Medical school gift restriction policies linked to subsequent prescribing behavior

Doctors who graduate from medical schools with an active policy on restricting gifts from the pharmaceutical industry are less likely to prescribe new drugs over existing alternatives, suggests a study published in BMJ today.

Medical that restrict gifts to physicians from the pharmaceutical and device industries are becoming increasingly common, but the effect of such policies on physician prescribing behaviour after graduation into clinical practice is unknown.

So a team of US researchers set out to examine whether attending a with a gift restriction policy affected subsequent prescribing of three newly marketed psychotropic (, antidepressant, and antipsychotic) drugs.

They identified 14 US medical schools with an active gift restriction policy in place by 2004.

They then analysed prescribing patterns in 2008 and 2009 of physicians attending one of these 14 schools compared with physicians graduating from the same schools before the policy was implemented, as well as a control sample of 20 schools that only adopted a gift restriction policy in 2008.

For two of the three drugs examined, attending a medical school with an active gift restriction policy was associated with reduced prescribing of the new drug over older alternatives within the same drug class.

A significant effect was not seen for the third drug.

Among students who had a longer exposure to the policy, or were exposed to more stringent policies, prescribing rates were further reduced.

"Our findings suggest that policies, which have been increasingly adopted by medical schools since 2002, may have the potential to substantially impact clinical practice and reduce prescribing of newly marketed pharmaceuticals," say the authors.

They add: "Future research examining the effect of these policies on medications with varying levels of innovativeness is necessary to establish whether medical school gift restriction policies reduce prescribing of all newly marketed medications or affect prescribing selectively."

add to favorites email to friend print save as pdf

Related Stories

Thousands of patients prescribed high-risk drugs

Jun 22, 2011

Thousands of patients in Scotland who are particularly vulnerable to adverse drug events (ADEs) were prescribed high-risk medications by their GPs which could potentially cause them harm, according to research published in ...

Recommended for you

Supercomputers link proteins to drug side effects

5 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

12 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments